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PVALVULAR HEART DISEASE
Metabolic Syndrome Is Associated
With More Pronounced Impairment
of Left Ventricle Geometry and Function
in Patients With Calcific Aortic Stenosis
A Substudy of the ASTRONOMER (Aortic Stenosis
Progression Observation Measuring Effects of Rosuvastatin)
Anik Pagé, BSC,* Jean G. Dumesnil, MD,* Marie-Annick Clavel, DVM,* Kwan L. Chan, MD,†
Koon K. Teo, MBBCH, PHD,§ James W. Tam, MD,‡ Patrick Mathieu, MD,*
Jean-Pierre Després, PHD,* Philippe Pibarot, DVM, PHD,* on behalf of the
ASTRONOMER Investigators
Quebec City, Quebec; Ottawa and Hamilton, Ontario; and Winnipeg, Manitoba, Canada
Objectives The aim of this study was to examine the relationship between metabolic syndrome (MetS) and left ventricular
(LV) geometry and function in patients with asymptomatic aortic stenosis (AS).
Background Recent experimental studies reveal that, among animals with sustained pressure overload, those with insulin
resistance induced by a high-carbohydrate/high-fat diet have more severe LV hypertrophy and dysfunction com-
pared to animals fed with standard diet.
Methods Among the 272 patients who were recruited in the ASTRONOMER (Aortic Stenosis Progression Observation Mea-
suring Effects of Rosuvastatin) study, none had hypercholesterolemia, diabetes mellitus, or coronary artery dis-
ease (exclusion criteria) at baseline. However, 33% had systemic hypertension and 27% had MetS as identified
by the National Cholesterol Education Program, Adult Treatment Panel III, clinical criteria.
Results Patients with MetS had higher LV mass index (53  14 g/m2.7 vs. 47  15 g/m2.7; p  0.002), relative wall
thickness ratio (0.47  0.09 vs. 0.42  0.09; p  0.001), and prevalence of LV concentric hypertrophy (42% vs.
23%) and lower peak early diastolic (8.2  2.4 cm/s vs. 9.6  3.1 cm/s, p  0.001) and peak systolic (7.9 
1.7 cm/s vs. 8.7  2.2 cm/s, p  0.009) mitral annular myocardial velocities compared to patients without
MetS. After adjustment for age, sex, low-density lipoprotein cholesterol, hypertension, and valvuloarterial imped-
ance (i.e., global LV hemodynamic load), MetS was independently associated with higher relative wall thickness
ratio (p  0.01), higher prevalence of concentric hypertrophy (p  0.03), and reduced diastolic (p  0.01) and
systolic (p  0.03) myocardial velocities.
Conclusions Notwithstanding AS severity and increase in hemodynamic load, MetS is independently associated with more pro-
nounced LV concentric hypertrophy and worse myocardial function in patients with AS, which may, in turn, predispose
them to the occurrence of adverse events. (Effects of Rosuvastatin on Aortic Stenosis Progression [ASTRONOMER];
NCT00800800) (J Am Coll Cardiol 2010;55:1867–74) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.11.083l
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aisceral obesity is associated with a cluster of metabolic
bnormalities often referred to as the metabolic syndrome
MetS), which includes insulin resistance, atherogenic dys-
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Impact of Metabolic Syndrome on LV Function in AS April 27, 2010:1867–74tional adipose tissue that is un-
able to appropriately store the
energy surplus resulting from a
sedentary lifestyle combined with
excessive calorie consumption (1).
Previous studies suggest that
MetS is associated with a 2-fold
increase in the relative risk of
coronary heart disease and stroke
events (2). Recently, MetS has
also been linked to increased
prevalence of aortic valve calcifi-
cation (3,4), faster progression of
calcific aortic stenosis (AS) (5),
increased arterial stiffness (6),
and faster degeneration of aortic
bioprosthetic valves (7). More-
over, recent experimental studies
(8,9) reveal that, among animals
with sustained pressure overload,
those with insulin resistance in-
uced by a high-carbohydrate/high-fat diet have more
evere left ventricular (LV) hypertrophy and dysfunction
ompared with animals fed a standard diet. These findings
uggest that the metabolic abnormalities associated with
isceral obesity might not only accelerate the progression of
he valvular lesion per se, but might also be associated with
orse LV remodeling and function in these patients with
alcific AS. We thus hypothesized that the dysmetabolic
tate linked to visceral obesity might pre-dispose to the
evelopment of more pronounced LV concentric hypertro-
hy and dysfunction in calcific AS.
The objective of this study was to examine the relation-
hips between MetS and: 1) the pattern of LV hypertrophy,
nd 2) the degree of LV diastolic and systolic dysfunction in
atients with asymptomatic AS. For the purpose of this
tudy, we analyzed the baseline data of the patients enrolled
n the ASTRONOMER (Aortic Stenosis Progression Ob-
ervation Measuring Effects of Rosuvastatin) study, a mul-
icenter randomized trial to evaluate the effects of rosuvas-
atin on the progression of AS (10).
ethods
atient population. Between 2002 and 2005, 272 pa-
ients with mild to moderate AS were recruited for the
STRONOMER study in 23 Canadian centers (10). Pa-
ients between 18 and 82 years of age with a peak Doppler
ortic valve velocity between 2.5 and 4.0 m/s were included.
atients were excluded if they had severe or symptomatic
S, severe aortic regurgitation, mitral valve disease (mitral
tenosis or severe mitral regurgitation), symptomatic coro-
ary artery disease, congestive heart failure, diabetes mellitus,
r need for cholesterol-lowering treatment. For the purpose of
his substudy, we analyzed the clinical, laboratory, and
Abbreviations
and Acronyms
AS  aortic stenosis
AVR  aortic valve
replacement
FFA  free fatty acid
HDL  high-density
lipoprotein
LDL  low-density
lipoprotein
LV  left ventricular
LVMi  left ventricular
mass index
MetS  metabolic
syndrome
RWT  relative wall
thickness ratio
Zva  valvuloarterial
impedanceoppler-echocardiographic data collected at baseline in 265 of rhe 272 patients recruited in the ASTRONOMER study. The
aist circumference was not available for 7 of 272 (2.5%)
atients.
linical and laboratory data. Clinical data included age,
ex, weight, height, body mass index, waist circumference,
istory of smoking, documented diagnosis of hypertension
patients receiving antihypertensive medications or having
nown but untreated hypertension: blood pressure130/85
m Hg).
Fasting blood samples were drawn to obtain glycemia,
nsulinemia, creatinin, and complete lipid profile, which
ncluded total cholesterol, triglycerides, low-density li-
oprotein (LDL) cholesterol, and high-density lipoprotein
HDL) cholesterol, using automated techniques standard-
zed with the Canadian reference laboratory. To assess
nsulin resistance, we calculated the homeostatic assessment
odel index using the formula: insulin (U/ml)  [glucose
mmol/l)/22.5] (11).
dentification of patients with MetS. The clinical identi-
cation of patients with the features of MetS was based on
he modified criteria proposed by the National Cholesterol
ducation Program, Adult Treatment Panel III (NCEP-
TPIII) (12). Patients were considered to have MetS when
of the 5 following criteria were present: elevated waist
ircumference (88 cm in women and 102 cm in men);
levated triglycerides (1.7 mmol/l or pharmacologic treat-
ent for hypertriglyceridemia); low HDL cholesterol (men
1.04 mmol/l and women 1.29 mmol/l); elevated blood
ressure (130/85 mm Hg or use of medications for
ypertension); and elevated fasting glucose (5.6 mmol/l).
oppler echocardiographic data. Parasternal and apical
iews were obtained using standard echocardiographic sys-
ems and multifrequency transducers with tissue Doppler
apability. Standard 2-dimensional images, M-mode, spec-
ral, color Doppler, and tissue Doppler imaging were
erformed.
ORTIC VALVE FUNCTION. The Doppler echocardio-
raphic indexes of AS severity included the peak and
ean transvalvular pressure gradient obtained with the
se of the modified Bernoulli equation and the aortic
alve area obtained with the use of the standard conti-
uity equation. The degree of calcification of the aortic
alve was scored according to the criteria proposed by
osenhek et al. (13): 1, no calcification; 2, mildly
alcified (isolated, small spots); 3, moderately calcified
multiple larger spots); and 4, heavily calcified (extensive
hickening/calcification of all cusps).
V REMODELING. The left ventricle minor axis internal
imension (LVID), posterior wall thickness (PWT), and
nterventricular septal thickness (IVST) were measured at
nd diastole in the left parasternal long-axis view according
o the recommendations of the American Society of Echo-
ardiography. Left ventricular mass was calculated with the
orrected formula of the American Society of Echocardiog-
aphy and was indexed to a 2.7 power of height (14). The
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April 27, 2010:1867–74 Impact of Metabolic Syndrome on LV Function in ASV hypertrophy was defined as an indexed LV mass
LVMi)49 g/m
2.7 in men and47 g/m2.7 in women (14).
he relative wall thickness ratio (RWT) was calculated with
he formula: RWT  (PWT  IVST)/LVID.
By taking into account both values of LVMi and relative
all thickness, patients were classified into 4 different LV
atterns using the following criteria adapted from those
roposed by Ganau et al. (15), as suggested by Cramariuc et
l. (16): 1) normal pattern: absence of LV hypertrophy and
WT ratio0.43; 2) concentric remodeling: absence of LV
ypertrophy and RWT ratio 0.43; 3) concentric hyper-
rophy: presence of LV hypertrophy and RWT 0.43; and
) eccentric hypertrophy: presence of LV hypertrophy and
WT 0.43.
V FUNCTION. Peak systolic (S-wave) and early diastolic
E-wave) myocardial velocities of the lateral aspect of the
itral annulus were measured by Doppler tissue imaging
17). Left ventricular ejection fraction was measured with
he use of the biplane Simpson method.
YSTEMIC ARTERIAL HEMODYNAMICS. Systemic arterial
ressure was measured with the use of an arm-cuff
phygmomanometer at the time of the Doppler echocar-
iographic examination. The ratio of LV outflow tract
troke volume index (SVi) to brachial pulse pressure (PP
systolic-diastolic blood pressure]) was used as an indirect
easure of total systemic arterial compliance: SAC 
Vi/PP (18). The stroke volume was indexed to a 2.04
ower of height (16).
LOBAL LV HEMODYNAMIC LOAD. As a measure of global
V hemodynamic load, we calculated the valvuloarterial
mpedance: Zva  (SBP  Pmean)/SVi, where SBP is the
ystolic blood pressure, Pmean is the mean transvalvular
radient, and SVi is the stroke volume indexed to a 2.04
ower of height (18); Zva represents the valvular and arterial
actors that oppose ventricular ejection.
tatistical analysis. Continuous data were expressed as
ean  SD. The continuous variables were tested for
ormality of distribution and homogeneity of variances with
he Shapiro-Wilk test and Levene test, respectively. These
ariables were then compared using the Student t test.
ategorical data were expressed as a percentage and com-
ared with the chi-square test. Multivariate linear regression
nalysis was performed to identify the variables indepen-
ently associated with LVMi, RWT ratio, E-wave velocity,
nd S-wave velocity. Multivariate logistic regression analysis
as used to identify the independent predictors of the
resence of concentric LV hypertrophy. The variables that
ere entered in these models were age, sex, LDL choles-
erol, hypertension, MetS, and Zva. A p value 0.05 was
onsidered significant.
esults
mong the 265 patients included in this study, 33% had
ystemic arterial hypertension, 38% had a history of smok-
l
mng, and 27% had MetS according to the NCEP-ATPIII
riteria. Patients who had MetS had larger body surface
rea, body mass index, and waist circumference, and higher
revalence of hypertension compared with patients who did
ot have MetS (Table 1). They were more frequently
reated with angiotensin-converting enzyme inhibitors or
ngiotensin-receptor blockers. They also had higher plasma
evels of triglycerides, glucose, and insulin, as well as higher
omeostatic assessment model index, and lower levels of
DL cholesterol; LDL cholesterol was similar in both
roups. Creatinin levels were similar in both groups.
Patients who had MetS had similar degree of valve
alcification, transvalvular gradient, and aortic valve area,
ut they had significantly lower systemic arterial compliance
nd higher Zva, compared with patients who did not have
etS (Table 2). The posterior wall thickness, interventric-
lar septum thickness, LVMi, and RWT ratio were higher
nd E- and S-wave velocities were lower in the MetS group
han in the no-MetS group. Left ventricular ejection frac-
ion was similar in both groups.
The distribution of LV remodeling patterns differed
ignificantly (p  0.01) between the MetS group and the
o-MetS group (Fig. 1). Among the patients with MetS,
0% had normal LV geometry and 42% had a concentric
V hypertrophy, compared with 37% and 23%, respectively,
mong the patients without MetS. The prevalence of
oncentric remodeling and eccentric hypertrophy was sim-
lar in both groups. Moreover, as shown in Figure 2, the
WT ratio increased with the number of MetS criteria
NCEP-ATPIII).
linical and Laboratory DataTable 1 Clinical and Laboratory Data
Variables
No MetS
(n  193, 73%)
MetS
(n  72, 27%) p Value
Age, yrs 57 14 60 12 0.07
Male, % 59.6% 66.7% NS
Height, cm 170 9 170 11 NS
Weight, kg 77 14 93 19 0.0001
Body surface area, m2 1.88 0.19 2.04 0.22 0.0001
Body mass index, kg/m2 26.7 4.3 32.4 6.8 0.0001
Waist circumference, cm 91.3 12.5 103.7 15.6 0.0001
History of hypertension, % 24.4% 56.9% 0.0001
History of smoking, % 36.8% 43.1% NS
LDL cholesterol, mmol/l 3.26 0.75 3.26 0.78 NS
HDL cholesterol, mmol/l 1.57 0.43 1.24 0.31 0.0001
Triglycerides, mmol/l 1.16 0.53 1.90 0.76 0.0001
Fasting glucose, mmol/l 5.13 0.51 5.7 0.80 0.0001
Fasting insulin, U/ml 6.54 4.88 13.77 8.38 0.0001
HOMA index 1.52 1.22 3.51 2.28 0.0001
Creatinin, mol/l 81 16 81 17 NS
Antihypertensive medication 17.1% 27.8% 0.01
ACE inhibitors 11.4% 17.7% NS
ARBs 5.7% 11.1% NS
alues are mean  SD or n (%).
ACE angiotensin-converting enzyme; ARB angiotensin-receptor blocker; HDL high-densityipoprotein; HOMA  homeostatic assessment model; LDL  low-density lipoprotein; MetS 
etabolic syndrome; NS  not significant.
u
a
m
T
h
v
f
n
c
(
L
o
v
i
t
5
o
e
w
E
t
w
h
h
r
1870 Pagé et al. JACC Vol. 55, No. 17, 2010
Impact of Metabolic Syndrome on LV Function in AS April 27, 2010:1867–74MetS was significantly related to increased LVMi on
nivariate analysis (p  0.002) but not on multivariate
nalysis (Table 3). In multivariate models that included age,
ale sex, LDL cholesterol, and hypertension (models 1 in
ables 3 and 4), MetS was independently associated with
igher RWT ratio and lower E- and S-wave myocardial
elocities. These independent associations persisted after
urther adjustment for Zva, namely, for the global hemody-
amic load (models 2 in Table 3) and for presence of
oncentric hypertrophy in the case of myocardial velocities
models 2 in Table 4). The only independent predictors of
VMi were male sex and elevated Zva; older age was the
nly other independent predictor of RWT ratio and E-wave
elocity. MetS (p  0.03) and age (p  0.01) were
Figure 1 Prevalence of Different Patterns of LV Remodeling/
Hypertrophy in Patients With or Without MetS
Percentage of patients with normal pattern, concentric remodeling (Conc.
Rem.), concentric hypertrophy (Conc. Hyper.), and eccentric hypertrophy (Ecc.
Hyper.) according to presence (blue bars) or absence (orange bars) of meta-
bolic syndrome (MetS).
Doppler-Echocardiographic DataTable 2 Doppler-Echocardiographic Data
Variables
Aortic valve calcification score
Aortic valve area, cm2
Indexed aortic valve area, cm2/m2.04
Peak gradient, mm Hg
Mean gradient, mm Hg
Systemic arterial compliance, ml·m2.04·mm Hg1
Valvuloarterial impedance, mm Hg·ml1·m2.04
LV end-diastolic diameter, mm
Posterior wall thickness, mm
Interventricular septum thickness, mm
Relative wall thickness ratio
LV mass index, g/m2.7
LV ejection fraction, %
S-wave velocity, cm/s
E-wave velocity, cm/s
LV  left ventricular; other abbreviations as in Table 1.ndependently associated with the presence of LV concen-
ric hypertrophy.
Separate univariate analyses of the associations among the
NCEP-ATPIII criteria used to identify MetS and the
utcome variables (Table 5) revealed that elevated triglyc-
rides, impaired fasting glucose, and elevated blood pressure
ere associated with higher RWT ratio and reduced
-wave velocity. Abdominal obesity was positively related
o LVMi and RWT, whereas only elevated blood pressure
as associated with reduced S-wave velocity. Elevated
omeostatic assessment model index was associated with
igher prevalence of concentric hypertrophy (p  0.03) and
educed E-wave velocity (p  0.02).
Figure 2 Relation Between Degree of Left Ventricular
Concentric Remodeling and Number of MetS Criteria
Relative wall thickness ratio as a function of the number of NCEP-ATPIII
(National Cholesterol Education Program, Adult Treatment Panel III) criteria of
the metabolic syndrome (MetS). Error bars represent standard errors of the
mean.
o MetS
193, 73%)
MetS
(n  72, 27%) p Value
.7 0.7 1.7 0.8 NS
35 0.42 1.35 0.44 NS
46 0.13 0.46 0.16 NS
41 11 41 11 NS
22 8 23 7 NS
70 0.23 0.63 0.24 0.05
.7 1.4 5.2 1.6 0.03
.6 6.6 49.9 6.3 NS
10 2 11 2 0.0003
11 2 12 2 0.0001
42 0.09 0.47 0.09 0.001
47 15 53 14 0.002
66 7 65 7 NS
.7 2.2 7.9 1.7 0.009
.6 3.1 8.2 2.4 0.001N
(n 
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April 27, 2010:1867–74 Impact of Metabolic Syndrome on LV Function in ASiscussion
he main finding of this study is that MetS is indepen-
ently associated with a markedly higher prevalence of LV
oncentric hypertrophy and with impaired myocardial dia-
tolic and systolic functions in patients with calcific AS.
hese associations persisted even after adjustment for arte-
ial hypertension and valvuloarterial impedance, a measure
f global LV hemodynamic load. These findings suggest
hat metabolic factors linked to visceral obesity are crucial
eterminants of LV remodeling and function in patients
ith AS.
otential mechanisms underlying association between
etS and LV remodeling in AS. Previous studies have
emonstrated that abnormal LV geometry is a powerful and
ndependent predictor of adverse outcomes in pressure
verload cardiomyopathies. In patients with systemic arte-
ial hypertension, there is a gradation of cardiovascular risk
ith each pattern of abnormal LV geometry, with concen-
ric hypertrophy conferring the highest risk, followed by
oncentric remodeling and lastly, by eccentric hypertrophy
19). In patients with AS, more severe LV concentric
emodeling or hypertrophy has been linked to worse myo-
ardial function (16,20,21) and increased operative and late
ortality after aortic valve replacement (22,23). In patients
ith no evidence of cardiovascular disease, previous studies
ave shown that obesity, MetS, and type 2 diabetes are
ssociated with higher prevalence of LV hypertrophy and
iastolic dysfunction (24–28). In the present study, we
emonstrate an independent association between MetS and
he presence of LV concentric hypertrophy and dysfunction
n patients with pressure overload secondary to aortic
tenosis. This is compounded in the one-third of patients
ith concomitant hypertension.
The dysmetabolic milieu of the viscerally obese patient
ay worsen myocardial remodeling and function by several
echanisms. 1) Visceral obesity is associated with a cluster of
etabolic abnormalities that are intricately related and include
nsulin resistance, activation of the renin-angiotensin sys-
em, low-grade inflammatory state, and activation of the
ympathetic nervous system. These factors may induce
ultivariate Predictors of Indexes of LV GeometryTable 3 Multivariate Predictors of Indexes of LV Geometry
Variables
LV Mass Index
Model 1 Mo
B Coeff. p Value B Coeff.
Age, yrs 0.01 0.85 0.11
Male 3.1 0.0009 3.0
LDL cholesterol, mmol/l 0.28 0.80 1.05
Hypertension 2.6 0.013 1.7
MetS 3.6 0.09 3.6
Zva, mm Hg·ml
1·m2.04 — — 1.73
he B coefficient (B Coeff.) is the raw-score regression coefficient.
Zva  valvuloarterial impedance; other abbreviations as in Tables 1 and 2.eripheral arterial vasoconstriction and aortic stiffening f6,29). This may, in turn, lead to the development of arterial
ypertension and thereby worsen the pressure overload
mposed on the left ventricle. However, given that the
ssociation between MetS and LV concentric hypertrophy
ersisted even after adjustment for hypertension and valvu-
oarterial impedance, it is likely that other metabolic factors
re involved in the adverse LV remodeling observed in
iscerally obese patients with AS. 2) Viscerally obese per-
ons also have an excess of epicardial fat that may participate
n abnormal myocardial remodeling and dysfunction (30).
n this regard, some investigators have hypothesized that
picardial fat cells may secrete locally acting cytokines
nd/or adipokines that may alter myocardial remodeling and
unction (30). 3) Obesity and MetS are associated with
mpaired coronary microvascular function, which may, in
urn, negatively impact myocardial perfusion and function
31). 4) In cardiac hypertrophic remodeling induced by
ressure overload, there is a shift in myocardial substrate
xidation from free fatty acids (FFAs) toward carbohydrates
9,32–34). Although initially beneficial, a sustained decline
n FFA oxidation due to hemodynamic overload may cause
n inappropriate accumulation of lipids in the hypertrophied
yocardium resulting in cellular toxicity (i.e., lipotoxicity
henomenon), contractile dysfunction, and eventually heart
ailure (35). Conversely, insulin resistance is associated with
everal alterations in plasma substrates of myocardial me-
abolism, mainly increased FFA and glucose levels (36,37).
ence, in the myocardium that is subjected to a reduction
n FFA oxidation due to hemodynamic overload, the pres-
nce of insulin resistance may further enhance the supply of
FA, thereby accentuating the accumulation of triglyceride
ithin the myocytes. In support of this hemodynamic-
etabolic stress interaction hypothesis, recent studies in
nimal models of pressure overload (8,9) reported that the
ysregulation of FFA metabolism, induced by a high-
arbohydrate/high-fat diet leads to excessive cardiac hyper-
rophy. In these models, there was a synergistic interaction
etween the hemodynamic load and the metabolic condi-
ion: namely, the LV mass increased and contractile effi-
iency decreased to a larger extent when the animals were
Relative Wall Thickness Ratio
Model 1 Model 2
p Value B Coeff. p Value B Coeff. p Value
0.18 0.002 0.0001 0.002 0.0001
0.002 0.002 0.68 0.003 0.64
0.41 0.006 0.40 0.009 0.26
0.13 0.005 0.40 0.006 0.38
0.31 0.036 0.005 0.033 0.01
0.014 — — 0.0003 0.95del 2ed a high-carbohydrate/high-fat diet.
C
s
o
m
i
t
a
a
N
w
M
f
a
i
a
d
e
e
k
t
S
o
d
e
m
h
a
f
a
i
w
c
s
g
g
s
i
t
p
i
h
s
S
e
f
t
L
t
p
a
a
s
h
i
a
p
M
T
3.
A
T
1872 Pagé et al. JACC Vol. 55, No. 17, 2010
Impact of Metabolic Syndrome on LV Function in AS April 27, 2010:1867–74linical implications. The results of the present study
uggest that the metabolic alterations linked to visceral
besity and insulin resistance may reduce the ability of the
yocardium to adapt to the additional hemodynamic load
mposed by AS. This aspect is novel and may have impor-
ant clinical implications. In our present study, 27% of
symptomatic patients, all without diabetes or coronary
rtery disease, have unrecognized MetS as defined by the
CEP-ATPIII criteria. In previous studies looking at the
ide spectrum of patients with calcific AS, the prevalence of
etS ranges from 30% to 40% (5,7). Therefore, MetS is a
requent condition in AS patients, largely undiagnosed
nd undertreated in clinical practice. Systematic screen-
ng for MetS in patients with AS should be undertaken,
long with aggressive lifestyle modification for those
iagnosed. Although statin therapy may positively influ-
nce some components of MetS (e.g., HDL and triglyc-
rides levels), it may have no or minimal effect on other
ey components such as visceral obesity, insulin resis-
ance, and proportion of small dense LDL particles.
pecific pharmacologic therapy directed toward visceral
besity or MetS will need to await results of prospectively
esigned clinical trials.
The results of this study also further emphasize that LV
jection fraction may markedly underestimate the extent of
yocardial impairment in the presence of LV concentric
ypertrophy, such as is generally the case for AS patients
nd especially for those with MetS. Indeed, LV ejection
raction is influenced by both intrinsic myocardial function
ultivariate Predictors of Indexes of LV FunctionTable 4 Multivariate Predictors of Indexes of LV Function
Variables
E-Wave Velocity
Model 1 M
B Coeff. p Value B Coeff.
Age, yrs 0.11 0.0001 0.10
Male 0.05 0.80 0.07
LDL cholesterol, mmol/l 0.36 0.16 0.51
Hypertension 0.05 0.83 0.08
MetS 1.05 0.02 1.25
Zva, mm Hg·ml
1·m2.04 — — 0.12
Conc. LVH — — 0.15
he B coefficient (B Coeff.) is the raw-score regression coefficient.
Conc. LVH  concentric left ventricular hypertrophy; other abbreviations as in Tables 1, 2, and
ssociation Between NCEP-ATPIII Criteria of Metabolic Syndrome aTable 5 Association Between NCEP-ATPIII Criteria of Metabolic
Variables
LVMi RW
B Coeff. p Value B Coeff.
Abdominal obesity 5.86 0.005 0.027
Elevated triglycerides 1.08 0.62 0.04
Low HDL cholesterol 3.94 0.11 0.015
Impaired fasting glucose 5.44 0.10 0.035
Elevated blood pressure 3.57 0.06 0.035he B coefficient (B Coeff.) is the raw-score regression coefficient.
LVMi  left ventricular mass index; RWT  relative wall thickness; other abbreviations as in Tables 1 and LV cavity geometry (20). Hence, for a similar extent of
ntrinsic myocardial shortening, the LV ejection fraction
ill tend to increase in relation to the extent of LV
oncentric remodeling. Indeed, the S-wave velocity was
ignificantly lower in the MetS group than in the no-MetS
roup although LV ejection fraction was similar in both
roups. These findings provide further impetus for the
ystematic utilization of tissue Doppler or strain rate imag-
ng to unmask the subclinical myocardial systolic dysfunc-
ion that is often not detected by LV ejection fraction in
atients with AS. This consideration becomes even more
mportant for the subset of patients with MetS given that, as
ighlighted in the present study, they are at higher risk for
ubclinical myocardial dysfunction.
tudy limitations. The purpose of the present study was to
xamine the impact of MetS on LV remodeling and
unction in patients with AS. The cross-sectional design of
his study limits the conclusion with regard to causality.
ongitudinal prospective studies are needed to investigate
he contribution of the cardiometabolic risk factors to the
rogression of AS severity and associated LV remodeling
nd dysfunction as well as the ability of pharmacologic
gents to halt or slow these disease processes.
The indexation of echocardiographic measures to body
urface area may result in an underestimation of LV
ypertrophy, an overestimation of AS severity (based on
ndexed valve area), and an overestimation of the valvulo-
rterial impedance in overweight or obese patients. In the
resent study, we compared 2 groups of patients with
S-Wave Velocity
2 Model 1 Model 2
p Value B Coeff. p Value B Coeff. p Value
0.0001 0.01 0.23 0.01 0.39
0.72 0.03 0.84 0.01 0.93
0.07 0.08 0.69 0.03 0.89
0.75 0.05 0.79 0.07 0.72
0.01 0.81 0.02 0.73 0.03
0.43 — — 0.18 0.14
0.75 — — 0.17 0.65
dexes of LV Geometry and Functiondrome and Indexes of LV Geometry and Function
o E-Wave S-Wave
p Value B Coeff. p Value B Coeff. p Value
0.025 0.84 0.08 0.35 0.28
0.001 1.08 0.02 0.41 0.23
0.32 0.09 0.87 0.70 0.09
0.006 1.72 0.001 0.51 0.16
0.002 1.35 0.002 0.70 0.02odelnd InSyn
T Ratind 2.
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April 27, 2010:1867–74 Impact of Metabolic Syndrome on LV Function in ASarkedly different body mass index (Table 1). Accordingly,
e chose to index LV mass, stroke volume, aortic valve area,
ystemic arterial compliance, and valvuloarterial impedance
o a power of height rather than to body surface area, as
uggested in previous studies (14,16).
onclusions
he results of the present study reveal that MetS is
ndependently associated with more pronounced LV con-
entric hypertrophy and worse myocardial diastolic and
ystolic function in patients with asymptomatic AS. These
ew findings combined with those of previous studies
uggest that the dysmetabolic state associated with visceral
besity may accelerate both the progression of the hemo-
ynamic severity of the stenosis and the deterioration of the
V geometry and function. Visceral obesity may present a
ovel therapeutic target in patients with calcific AS. Pro-
pective longitudinal studies are needed to further establish
he link between the metabolic abnormalities associated
ith visceral obesity and disease progression in patients with
alcific AS.
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